Related Experiment Video
Updated: Feb 16, 2026

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
Vedolizumab-induced acute pancreatitis: the first reported clinical case
Sherman Picardo1, Kenji So1, Kannan Venugopal1
1Department of Gastroenterology, Royal Perth Hospital, Perth, Western Australia, Australia.
Abstract:
Drug-induced acute pancreatitis (DIAP) is a rare, but clinically significant diagnosis. Vedolizumab, an α4β7 integrin inhibitor, which was approved in 2015 for treatment of moderate to severe inflammatory bowel disease, is a well-tolerated medication with a favourable safety profile and minimal serious adverse events in premarketing clinical trials. We present the first reported case of acute pancreatitis directly attributable to vedolizumab.
More Related Videos
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Kidney Injury III: Clinical Manifestations
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:

